Products Enoxaparin is commercially available as a solution for injection (Clexane). It has been approved in many countries since 1988. Biosimilars were released in the EU in 2016 and in many countries in 2020 (Inhixa). Structure and properties Enoxaparin is present in the drug as enoxaparin sodium, the sodium salt of a low-molecular-weight heparin (LMWH) … Enoxaparin
Products Nadroparin is commercially available as a solution for injection (Fraxiparine, Fraxiforte). It has been approved in many countries since 1988. Structure and properties Nadroparin is present in the drug as nadroparin calcium. It is the calcium salt of a low-molecular-weight heparin obtained by depolymerization of heparin from the intestinal mucosa of pigs using nitrous … Nadroparin
Products Injection preparations are approved as medicinal products. Structure and properties Injection preparations are sterile solutions, emulsions, or suspensions prepared by dissolving, emulsifying, or suspending the active ingredient and excipients in water or a suitable nonaqueous liquid (e.g., fatty oils). Compared with infusions, these are usually small volumes in the range of less than a … Injections
Products Low-molecular-weight heparins are commercially available as injectable solutions, in the form of prefilled syringes, ampoules, and lancing ampoules. The active ingredients now commonly used in many countries were first approved in the late 1980s. Biosimilars are available in some countries. The active ingredients are abbreviated in English with the acronym LMWH (low molecular weight … Low-Molecular-Weight Heparins
Symptoms Possible symptoms of a bruise (technical term: hematoma) include swelling, pain, inflammation, and discoloration of the skin that changes (red, blue, purple, green, yellow, brown) during the healing process. This text refers to simple and small-surface complaints that can be considered for self-medication. Causes The cause of a hematoma is blood leaking from injured … Bruise (Hematoma) Symptoms and Causes
Symptoms Shortly after an injection, some patients may experience the following symptoms: Pallor Malaise Dry mouth Cold sweat Low blood pressure Drowsiness, dizziness, confusion Nausea Fainting, syncope (short-lasting circulatory collapse). Convulsions (seizures) ECG changes Falls, accidents These disorders occur, for example, shortly after a vaccination, after parenteral administration of drugs, during acupuncture or blood sampling. … Fear of Injections
Products Dalteparin is commercially available as an injectable (Fragmin). It has been approved in many countries since 1988. Structure and properties Dalteparin is present in drugs as dalteparin sodium, the sodium salt of a low-molecular-weight heparin obtained by depolymerization of heparin from porcine intestinal mucosa using nitrous acid. The average molecular weight is 6000 Da. … Dalteparin
Symptoms A heart attack manifests itself in acute and severe pain and a feeling of tightness and pressure in the chest, which may also radiate to the arms, jaw or abdomen. Other symptoms include nausea, indigestion, shortness of breath, coughing, a break of sweat, pallor, fear of death, unconsciousness and dizziness. A myocardial infarction lasts … Heart Attack Causes and Treatment
Products Direct oral anticoagulants (abbreviation: DOAKs) are commercially available in the form of film-coated tablets and capsules. By definition, they are oral drugs. Some representatives of the corresponding drug groups are also available as infusion preparations. Rivaroxaban (Xarelto) and dabigatran (Pradaxa) were the first active ingredients to be approved in 2008. The DOAKs were developed … DOAK
Symptoms The possible symptoms and signs of deep vein thrombosis include: Pain or cramping in the legs Swelling (edema), feeling of tension Warmth sensation, overheating Reddish to blue-purple discoloration of the skin Increased visibility of the superficial veins The symptoms are rather nonspecific. Deep vein thrombosis may also be asymptomatic and discovered by chance. A … Deep Vein Thrombosis
Products Direct factor Xa inhibitors are commercially available in the form of film-coated tablets and capsules. In 2008, rivaroxaban (Xarelto) was the first agent in this group to be approved in many countries and in the EU. Today, there are other drugs on the market, which are listed below. Like thrombin inhibitors, these active ingredients … Factor Xa Inhibitors
Products Biosimilars are copycat preparations of biotechnology-derived drugs (biologics) that have strong similarities to the originator drugs but that are not exactly the same. The similarity relates to biological activity, structure, function, purity and safety, among other things. Biosimilars differ from generics of small molecule drugs in important ways. Biosimilars are usually marketed as injection … Biosimilars
